Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMFNUHQ)

• Drug Name: 8-chloro-quinoline-3-carbonitrile Drug Info
• Synonyms: CHEMBL436817; Cyanoquinoline, 11; SCHEMBL6071997; BDBM21898; CHEBI:94979; BRD-K00088062-001-01-3; 4-[(3-Chloro-4-fluorophenyl)amino]-6-[(1H-imidazole-5-ylmethyl)amino]-8-chloro-3-quinolinecarbonitrile

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 17759555
  ChEBI ID: CHEBI:94979
  TTD Drug ID: DMFNUHQ

Molecule-Related Drug Atlas

Drug(s) Targeting Cot oncogene messenger RNA (MAP3K8 mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
NSC-686549	DM0164B	Discovery agent	N.A.	Investigative	[2]
ISIS 116361	DMWBQHS	Discovery agent	N.A.	Investigative	[3]
Tpl2 kinase inhibitor	DMHATCZ	Discovery agent	N.A.	Investigative	[4]
ISIS 116414	DM4Q3JO	Discovery agent	N.A.	Investigative	[3]
ISIS 116360	DMFEZHM	Discovery agent	N.A.	Investigative	[3]
ISIS 116359	DM280AE	Discovery agent	N.A.	Investigative	[3]
ISIS 116362	DM7M1UB	Discovery agent	N.A.	Investigative	[3]
ISIS 116363	DMXKAJP	Discovery agent	N.A.	Investigative	[3]

Drug(s) Targeting Matrix metalloproteinase-3 (MMP-3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PMID29130358-Compound-Figure10(2a)	DMFWXPS	N. A.	N. A.	Patented	[5]
GM6001	DM7V9CT	Corneal ulcer	9A76	Discontinued in Phase 2	[6]
RS-130830	DMOTANY	Hepatitis C virus infection	1E51.1	Discontinued in Phase 2	[7]
PG-530742	DMELXBQ	Myocardial infarction	BA41-BA43	Discontinued in Phase 2	[8]
Batimastat	DM92VRP	Idiopathic pulmonary fibrosis	CB03.4	Preclinical	[9]
SC-44463	DMBPNKT	N. A.	N. A.	Terminated	[10]
BB-1101	DM7GH5Z	Multiple sclerosis	8A40	Terminated	[11]
L-696418	DMV785R	N. A.	N. A.	Terminated	[12]
RO-319790	DML3NEU	Rheumatoid arthritis	FA20	Terminated	[13]
MMI270	DM38N2K	Discovery agent	N.A.	Investigative	[14]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Cot oncogene messenger RNA (MAP3K8 mRNA)	TTGECUM	M3K8_HUMAN	Inhibitor	[1]
Matrix metalloproteinase-3 (MMP-3)	TTUZ2L5	MMP3_HUMAN	Inhibitor	[1]

References

• [1] Pharmacologic inhibition of tpl2 blocks inflammatory responses in primary human monocytes, synoviocytes, and blood. J Biol Chem. 2007 Nov 16;282(46):33295-304.
• [2] A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8.
• [3] US patent application no. 6,265,216, Antisense modulation of cot oncogene expression.
• [4] Inhibition of Tpl2 kinase and TNF-alpha production with 1,7-naphthyridine-3-carbonitriles: synthesis and structure-activity relationships. Bioorg Med Chem Lett. 2005 Dec 1;15(23):5288-92.
• [5] Gelatinase inhibitors: a patent review (2011-2017).Expert Opin Ther Pat. 2018 Jan;28(1):31-46.
• [6] Introduction of the 4-(4-bromophenyl)benzenesulfonyl group to hydrazide analogs of Ilomastat leads to potent gelatinase B (MMP-9) inhibitors with i... Bioorg Med Chem. 2008 Sep 15;16(18):8745-59.
• [7] Structure-based design of potent and selective inhibitors of collagenase-3 (MMP-13). Bioorg Med Chem Lett. 2005 Feb 15;15(4):1101-6.
• [8] Selective matrix metalloproteinase inhibition attenuates progression of left ventricular dysfunction and remodeling in dogs with chronic heart fail... Am J Physiol Heart Circ Physiol. 2006 Jun;290(6):H2522-7.
• [9] Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice. Cancer Res. 1994 Sep 1;54(17):4726-8.
• [10] Amide surrogates of matrix metalloproteinase inhibitors: Urea and sulfonamide mimics, Bioorg. Med. Chem. Lett. 7(18):2331-2336 (1997).
• [11] Broad spectrum matrix metalloproteinase inhibitors: an examination of succinamide hydroxamate inhibitors with P1 C alpha gem-disubstitution. Bioorg Med Chem Lett. 1998 Jun 16;8(12):1443-8.
• [12] Inhibition of matrix metalloproteinases by N-carboxyalkyl peptides containing extended alkyl residues At P1', Bioorg. Med. Chem. Lett. 5(6):539-542 (1995).
• [13] The asymmetric synthesis and in vitro characterization of succinyl mercaptoalcohol and mercaptoketone inhibitors of matrix metalloproteinases. Bioorg Med Chem Lett. 1998 May 19;8(10):1163-8.
• [14] Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer. 2002 Sep;2(9):657-72.